On March 29, 2020, AbCellera Biologics, Inc., a biopharmaceutical company based in New York City, announced that it has entered into a multi-year licensing agreement to develop a new antibody to treat cancer.  The agreement is subject to approval by the U.S. Department of Health and Human Services.  According to the SEC's complaint filed in federal court in Manhattan, AbCellera has been unable to develop a single antibody to treat cancer.  The SEC's complaint, filed in federal court in Manhattan, charges AbCellera with violating Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, AbCellera has agreed to the entry of a final judgment that permanently enjoins it from violating Sections 17(a)(1) and (3) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and orders it to pay a $2.6 million civil penalty.  The settlement is subject to court approval.  The SEC's complaint charges AbCellera with violating Sections 206(1) and 206(2) of the Investment Advisers Act of 1940 and Rule 206(4)-8 thereunder.  Without admitting or denying the SEC's allegations in the complaint, AbCellera has consented to the entry of a final judgment permanently enjoining it from violating Sections 206(1) and (2) of the Investment Advisers Act and Rule 206(4)-8 thereunder, and ordering it to pay a civil penalty of $2.6 million.  The settlement is subject to Court approval.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued an Investor Alert to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool on Investor.gov.